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Abstract
Purpose Transforming growth factor (TGF)-β is a key
mediator of proliferative vitreoretinopathy, but the cellular
mechanisms by which TGF-β induces extracellular matrix
protein (ECM) synthesis are not fully understood. This
study examined whether the PI3K/Akt pathway is involved
in TGF-β2-induced collagen expression in human retinal
pigment epithelial cells.
Methods Human retinal pigment epithelial cells ARPE-19
were cultured and stimulated with TGF-β2. The role of the
PI3K/Akt pathway was evaluated using the biochemical
inhibitor, wortmannin. The effect of wortmannin on the
expression of type I collagen mRNA (COL1A1, COL1A2)
induced by TGF-β2 was evaluated by real-time RT-PCR.
The effect of wortmannin on the synthesis of type I
collagen induced by TGF-β2 was assessed by an immuno-
cytochemical analysis with anti-type I collagen antibody.
Luciferase reporter assays were performed to examine the
effect of wortmannin on the transcriptional activities of
COL1A2. A luciferase assay using a mutation construct of
the Smad binding site in COL1A2 promoter (Smad-mut/Luc)
was also performed to examine the crosstalk between the
Smad pathway and the PI3K/Akt pathway. The effects of
wortmanninonthetranscriptionalactivityofSmad3werealso
examined using CAGA12-Luc. Moreover, the effect of
wortmannin on TGF-β2-induced Smad7 mRNA expression
was evaluated.
Results The biochemical blockade of PI3K/Akt activa-
tion inhibited TGF-β2-induced type I collagen mRNA
expression and type I collagen synthesis. The blockade
of PI3K/Akt pathway inhibited the increase in COL1A2
promoter activities when induced by TGF-β2a n d
reduced TGF-β2 induction of Smad-mut/Luc promoter
activity and CAGA12-Luc activity. Moreover, wortman-
nin increased the TGF-β2-induced Smad7 mRNA
expression levels.
Conclusions The PI3K/Akt pathway plays a role in
relaying the TGF-β2 signal to induce type I collagen
synthesis in the retinal pigment epithelium through Smad-
dependent and Smad-independent pathways.
Keywords Retinal pigment epithelium.TGF-β.Collagen.
PI3K/Akt.Vitreoretinopathy
Introduction
Proliferative vitreoretinopathy (PVR) is a major cause of
the failure of rhegmatogenous retinal detachment surgery
[1, 2]. It is characterized by extracellular matrix (ECM)
accumulation in the vitreous cavity and on the inner or
outer surfaces of the neural retina [3]. PVR reduces the
flexibility of the retina and makes it difficult to reattach the
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studies have shown that retinal pigment epithelial (RPE)
cells play a critical role in the pathogenesis of PVR [4–8].
RPE cells are stimulated by various cytokines following
rhegmatogenous retinal detachment. These activated RPE
cells undergo transformation to fibroblast-like cells, prolif-
erate, migrate through retinal tears and produce ECM to
form pathologic membranes [4, 6].
The ECM in PVR membranes contains various proteins
including collagen, elastin and fibronectin. Type I collagen
is the major structural component of the ECM in PVR
membranes [5, 6]. This is a heterotrimer composed of
coordinately expressed two α1 chains and one α2 chain.
They are encoded by distinct genes, namely COL1A1 and
COL1A2 respectively, and their expression is modulated by
various cytokines [9].
Transforming growth factor-β (TGF-β) is a member of a
superfamily of multifunctional cytokines which mediate
development, wound repair, and other pathologic processes
in many cell types [10]. Three isoforms of TGF-β, namely
TGF-β1, β2 and β3, are present in mammalian tissues.
Although in vitro experiments often elicit similar responses,
their in vivo roles and expression are not uniform [11].
TGF-β plays a critical role in ECM protein synthesis and
accumulation, and is a key mediator of fibrous diseases
including pulmonary fibrosis [12], liver cirrhosis [13],
and human skin fibrosis [14]. Evidence for high concen-
trations of TGF-β2 in vitreous aspirates from patients with
PVR has highlighted its importance in PVR. It should be
noted that immunologic assays showed that most TGF-β
in the vitreous aspirates were TGF-β2i s o f o r m ,n o tT G F -
β1[ 15, 16].
Phosphoinositide 3-kinase (PI3K), which contains p85
catalytic and p110 regulatory subunits, plays a crucial role
as a mediator of growth factor signaling, cell proliferation,
cell survival, and apoptotic inhibition. The serine/threonine
kinase Akt is an important target of PI3K-generated signals.
Akt phosphorylates multiple proteins implicated in cell
cycle control to ultimately stimulate cell growth [17]. In
some cells, including mesangial cells, skin fibroblasts and
human lens epithelial cells, the PI3K/Akt signaling pathway
plays a role in either the TGF-β induction of type I collagen
expression or epithelial mesenchymal transition [18–21].
However, the role of the PI3K-Akt pathway in TGF-β-
induced collagen expression has not been fully investigated
in human RPE.
We and the other researchers previously showed that
Smad, p38 MAPK and RhoA/Rho-kinase pathways medi-
ate the expression of type I collagen induced by TGF-β2i n
retinal pigment epithelial cells [11, 22, 23]. The current
study was conducted to examine whether the PI3K/Akt
pathway is involved in the TGF-β2-induced collagen
expression of RPE cells.
Materials and methods
Reagents
Recombinant human TGF-β2 was purchased from R&D
Systems (Minneapolis, MN, USA). Wortmannin, a PI3K
inhibitor, was purchased from Sigma (St. Louis, MO,
USA). Antibodies were purchased from various ven-
dors: anti-PI3K p85 and anti-phospho-PI3K p85 were
from Cell Signaling Technology (Beverly, MA, USA).
Anti-phospho-Akt, anti-Akt were from SABiosciences
(Frederick, MN, USA). Anti-human type I collagen
mouse monoclonal antibody was from Southern Biotech
(Birmingham, AL, USA). Secondary anti-mouse IgG2b
antibody was from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). DAPI solution was from DOJNJO
Laboratories (Kumamoto, Japan).
Cell culture and stimulation by TGF-β2
The cells of the human retinal pigment epithelial line
ARPE-19 were obtained from the American Type Culture
Collection (ATCC; Manassas, VA, USA). ARPE-19 is an
immortalized, nontransfected cell line that spontaneously
arose from cultures of human RPE. Cells were maintained
in 1:1 (vol/vol) mixture of Dulbecco’s modified Eagle’s and
Ham’s F12 medium (DMEM/F12; ATCC) supplemented
with 10% heat-inactivated fetal bovine serum (FBS; Sanko
Junyaku, Tokyo, Japan) and antibiotics (100 U/ml penicillin
G and 100 μg/ml streptomycin sulfate) in a humidified
incubator at 37°C in 5% CO2. Cells were used at passage
numbers 13 to 18 in the present studies.
The medium was removed from confluent cultures and
replaced with serum-free DMEM/F12. After 24 hours of
serum starvation, 10 ng/ml of TGF-β2 was added to the
medium, and the cultures were incubated another 24 hours
for RNA isolation and protein analysis. The cells were
preincubated for 30 minutes before treatment with or
without exogenous TGF-β2 prior to treatment with the
PI3K inhibitor wortmannin.
Western blot analysis of PI3K p85 activation
Cells grown to confluence were cultured for 24 h with
serum-free medium, and then were treated with 10 ng/ml of
TGF-β2 for different periods of time with or without
wortmannin. The cells were washed twice with ice-cold
phosphate buffered saline (PBS), then lysed on ice in
M-PER Mammalian Protein Extraction Reagent containing
protease and phosphatase inhibitors (Pierce, Rockford, IL,
USA). Cell extracts were centrifuged at 15,000 g for 10 min
at 4°C, supernatants were collected, and the protein content
was determined using the BCA Protein Assay Reagent kit
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(0.125 M Tris-HCl (pH 6.8), 4% SDS, 20% glycerol,
0.002%bromophenolblue,10%2-mercaptoethanol).Samples
were resolved by SDS-PAGE and electroblotted onto a
polyvinylidene difluoride (PVDF) membrane. Equal loading
and appropriate transfer of each lane was confirmed by
staining the PVDF membrane with the Ponceau S solution
(Sigma). After blocking with a PVDF blocking reagent
(TOYOBO, Osaka, Japan) for 1 h at room temperature,
membraneswere incubatedwithananti-PI3Kp85 antibodyor
anti-phospho-PI3K p85 antibody overnight at 4°C, followed
by incubation with the horseradish peroxidase (HRP)-
conjugated anti-rabbit IgG for 1 h at room temperature.
The signals were enhanced using a chemiluminescence
system (ECL plus; Amersham Pharmacia Biotech,
Buckinghamshire, England) and exposed to X-ray film.
Quantification of activation of Akt
Cells were seeded in 96-well plates, incubated in medium
containing 10% FBS and grown to confluence. The
medium was changed to serum-free DMEM/F12 for 24 h,
followedbyincubationinthepresenceofTGF-β2(10ng/mL)
for different periods with or without wortmannin. Akt
activation by TGF-β2 was quantified by using a CASE™
kit for Akt according to the manufacturer’s instructions
(SuperArray Biosciences, Frederick, MD, USA). Cells were
fixed with 8% formaldehyde for 30 min and processed for
ELISA measurements with anti-pS473-Akt or anti-Akt
antibodies. The bound antibodies were then detected
withanti-mouseacetylcholineesteraseconjugate,followedby
color development. Absorbance at 450 nm was determined
using a microplate spectrophotometer.
RNA isolation and cDNA synthesis
Total RNA was prepared using a minikit (RNeasy; Qiagen,
Valencia, CA, USA). Cells in lysis buffer containing 1% β-
mercaptoethanol were passed through a separation column
(QIA Shredder; Qiagen), and total RNA was obtained
according to the manufacturer’s protocol. cDNA was
produced with a kit (High Capacity cDNA Reverse
Transcription Kit; Applied Biosystems), using random
hexamers.
Real-time PCR
Real-time PCR was performed using a sequence-detection
system (Prism TM 7300; Applied Biosystems). The
sequence-specific primers and probe mixtures for human
COL1A1, COL1A2, Smad7 and human GAPDH (used as
an internal control gene) were from predeveloped assays
(TaqMan® Gene Expression assays; Applied Biosystems).
The thermal cycling conditions included one cycle at 50°C
for 2 minutes, one cycle at 95°C for 10 minutes, and 40
cycles at 95°C for 15 seconds and 60°C for 1 minute. The
relative mRNA expression levels of COL1A1, COL1A2
and Smad7 were normalized against the GAPDH gene from
the same RNA preparations, using a comparative threshold
cycle method.
Plasmid constructs
The COL1A2/luciferase (COL1A2/Luc) construct contain-
ing the 436-bp sequence of the COL1A2 promoter and the
mutated Smad binding consensus sequence in the
COL1A2/Luc (Smad-mut/Luc) were used in these experi-
ments. These have been previously described [22].
CAGA12-Luc is a reporter gene containing 12 repeats of
the Smad binding element, and was kindly provided by Dr.
Christina Stuelten (NIH).
Immunocytochemical analysis
ARPE-19 cells were seeded in the wells of chamber slides
(Nunc, Naperville, IL, USA) in DMEM/F12 supplemented
with 10% FBS and grown to subconfluence. The medium
was changed to serum-free DMEM/F12 for 24 h, followed
by incubation in the presence or absence of 10 ng/ml of
TGF-β2, with or without wortmannin, in medium contain-
ing 200 μM of L-ascorbic acid 2-phosphate (Wako Pure
Chemical Industries, Osaka, Japan). The cells were then
fixed in 4% paraformaldehyde, permeabilized with 0.1%
Triton X-100, then blocked with 0.5% bovine serum
albumin. The specimens were then processed for immuno-
fluorescence staining with a monoclonal anti-human type I
collagen antibody (1:200 dilution in phosphate-buffered
saline). Cells were then incubated with FITC-conjugated
anti-mouse IgG and DAPI for an hour at room temperature,
and deposition of the type I collagen in each cell was
photographed and analyzed.
Transient transfection and luciferase assays
The transcriptional activity of COL1A2 was determined by
transient transfection of ARPE-19 cells. The EndoFree
Plasmid Maxi kit (Qiagen) was used to purify the plasmids.
ARPE-19 cells were transfected using Effectence Transfec-
tion Reagent (Qiagen). Cells were seeded in the plate the
day before transfection. Cells were transfected at 60-80%
confluence according to the manufacturer’s recommenda-
tions. Six hours later, cells were stimulated with or without
TGF-β2 (10 ng/ml) in the presence or absence of wort-
mannin for an additional 24 h. The cells were lysed and
assayed using the dual luciferase reporter assay system
(Promega).
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(Lumat LB.9507, EG and G, Berthold, Germany). A
construct containing renilla luciferase (pRL-TK, Promega)
was cotransfected with COL1A2/Luc or Smad-mut/Luc,
and used as a control for transfection efficiency. The values
were expressed relative to the activity in non-treated cells.
CAGA12-Luc was transfected with or without TGF-β2
(10 ng/ml) in the presence or absence of wortmannin to
assess the effects of wortmannin on the transcriptional
activity of Smad3.
Statistical analysis
The values represent the means ± SD of multiple
independent tests. The Wilcoxon signed-rank test was used
to evaluate any statistical significance between the groups,
and p<0.05 was considered to be significant.
Results
Effect of TGF-β2 on PI3K/Akt activation
We first examined the expression levels of phospho-PI3K
and phospho-Akt proteins expression in ARPE-19 cells
treated with exogenous TGF-β2 (10 ng/ml) by a Western
analysis and ELISA. The anti-phospho-PI3K p85 and anti-
phospho-Akt antibodies specifically detects the phosphory-
lated forms of PI3K p85 and Akt respectively, whereas the
anti-PI3K p85 and anti-Akt antibody detects total PI3K
p85 or Akt protein. TGF-β2 increased the phosphorylation
of PI3K p85 and Akt within 5 minutes after stimulation, and
those activations persisted for 24 hours. Preincubation of
ARPE-19withwortmanninblockedthe TGF-β2-inducedAkt
activation (Fig. 1).
Effect of wortmannin on the type I collagen mRNA
expression by TGF-β2
Exogenous TGF-β2 induces PI3K/Akt phosphorylation in
ARPE-19 cells. The effect of wortmannin (10 μM) on
TGF-β2 (10 ng/ml) induction of type I collagen mRNA
(COL1A1 and COL1A2) expression was evaluated by real-
time RT-PCR. Cells expressed a basal level of type I
collagen genes, and type I collagen mRNA expression
increased markedly following treatment with exogenous
TGF-β2[ 18]. Preincubation of ARPE-19 with wortmannin
significantly reduced the expression of type I collagen
mRNA (Fig. 2). Inhibitor treatment had very little effect on
the basal levels of type I collagen mRNA expression. These
results indicated that the PI3K/Akt pathway mediates TGF-
β2-induced expression of COL1A1 and COL1A2 mRNAs.
Fig. 1 PI3K p85 and Akt activation induced by TGF-β2 in ARPE-19
cells. a PI3K p85 activation: lysates from cells pretreated with or
without wortmannin (10 μM) and incubated in the presence or
absence of TGF-β2 (10 ng/ml) for 5 min or 24 h. Bands
corresponding to the phosphorylated form of PI3K p85 (top) and
total PI3K p85 (bottom) were detected. Wortmannin did not inhibit
TGF-β2-induced PI3K p85 activation. b Akt activation: lysates from
cells incubated in the presence of TGF-β2w i t ho rw i t h o u t
pretreatment with wortmannin were analyzed using a kit. Wortmannin
inhibited TGF-β2-induced Akt activation. Data represent the means ±
SD of three independent experiments. *P<0.01, in comparison to no
stimulation with TGF-β2
Fig. 2 Effects of wortmannin on TGF-β2-induced COL1A1 and
COL1A2 mRNA expression. Quiescent cells were pretreated with or
without wortmannin and incubated in the presence or absence of TGF-
β2 (10 ng/ml) for 24 hours. The relative levels of mRNA were
normalized against GAPDH from the same cDNA preparation. Values
represent the means ± SD of three independent experiments. *P<0.01,
in comparison to stimulation with TGF-β2 and without inhibitors
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activity induced by TGF-β2
The effect of wortmannin on TGF-β2 induction of the
COL1A2/Luc promoter was investigated in ARPE-19 cells
(Fig. 3). Treatment with wortmannin significantly reduced
the COL1A2/Luc promoter activity induced by TGF-β2.
The inhibitor treatment had little effect on the basal
promoter activities of COL1A2/Luc. These findings indi-
cated that the PI3K/Akt pathway is involved in the
transcriptional activation of COL1A2 by TGF-β2.
Immunocytochemical observation of ARPE-19 treated
with wortmannin in the presence of TGF-β2
ARPE-19 cells were immunostained to examine whether
the expression of type I collagen protein was correlated
with the inhibition of gene expression and promoter activity
by wortmannin, in the presence or absence of TGF-β2.
Increased expression of type I collagen was observed in cells
treatedwith TGF-β2i nc om p ar i s ont oco n t ro l s( F i g.4a and b).
On the other hand, addition of wortmannin to ARPE-19 cells
treated with TGF-β2 dramatically inhibited the expression of
type I collagen (Fig. 4c).
Effect of wortmannin on the Smad-mut/Luc promoter
and CAGA12-Luc activity induced by TGF-β2
TGF-β2 signals from the cell surface to the nucleus are
transduced by Smad2,-3 and-4, and phosphorylation of
Smad2/3 is crucial for this downstream signaling
cascade. Smad protein mediates TGF-β signaling and
stimulates COL1A2 mRNA expression. Therefore, the role of
wortmannin on regulating the mutated Smad binding site
construct (Smad-mut/Luc) was evaluated in ARPE-19 cells.
Fig. 3 Effects of wortmannin on TGF-β2-induced COL1A2 promoter
activity in ARPE-19 cells. Transfected cells were pretreated with or
without wortmannin and incubated in the presence or absence of TGF-
β2 (10 ng/ml) for 24 hours. Results are expressed relative to untreated
control cells. Values represent the means ± SD of three independent
experiments. *P<0.01, in comparison to stimulation with TGF-β2 and
without inhibitors
Fig. 4 Wortmannin reduces the
production of TGF-β2-induced
type I collagen in ARPE-19
cells. Cells were preincubated
with vehicle or wortmannin (c)
for 30 min and incubated in the
absence (a) or presence (b,c)
of TGF-β2 (10 ng/mL) for 24 h.
Bar:100 μm
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was significantly diminished, in comparison to the activity
of COL1A2/Luc (Fig. 5). Moreover, treatment with
wortmannin reduced TGF-β2 induction of Smad-mut/Luc
promoter activity. On the other hand, wortmannin signifi-
cantly reduced CAGA12-Luc, a reporter gene containing 12
repeats of the Smad binding element, induction by TGF-β2
(Fig. 6). These findings indicated that the PI3K/Akt
pathway mediates type I collagen expression induced by
TGF-β2 in ARPE-19 cells through Smad-independent and
Smad-dependent pathways.
Effect of wortmannin on the Smad7 mRNA
expression induced by TGF-β2
Smad7, an inhibitory Smad, is a key regulator of TGF-β
signaling by negative feedback loop. The effect of
wortmannin (10 μM) on TGF-β2 (10 ng/ml) induction of
Smad7 mRNA expression was evaluated in ARPE-19 by
real-time RT-PCR. Preincubation of ARPE-19 with wort-
mannin increased the expression levels of TGF-β2-induced
Smad7 mRNA (Fig. 7).
Discussion
This study examined the role of PI3K/Akt signaling
cascades in mediating the effects of TGF-β2 on type I
collagen synthesis in the human retinal pigment epithelial
cell line, ARPE-19. The results suggest that the PI3K/Akt
pathway could be involved in TGF-β2-induced collagen
synthesis in ARPE-19 cells. Treatment with wortmannin, an
inhibitor of the PI3K/Akt pathway, significantly reduced
mRNA, promoter activity, and the expression of type I
collagen protein in response to TGF-β2 in ARPE-19. Type
I collagen is the major structural component of the
extracellular matrix in fibrous disease in the lung [12],
liver [13], skin [14], eye [11, 24]. Studies of these diseases
have shown that type I collagen synthesis is influenced by
various cytokines including platelet-derived growth factor
(PDGF) [25], basic fibroblast growth factor (bFGF) [26]
and TGF-β [27]. In particular, the TGF-β family is a key
Fig. 6 Effects of wortmannin on TGF-β2-induced CAGA12-Luc
activity in ARPE-19 cells. Transfected cells were pretreated with or
without wortmannin and incubated in the presence or absence of TGF-
β2 (10 ng/mL) for 24 hours. Results are expressed relative to
untreated control cells. Values represent the means ± SD of three
independent experiments. *P<0.01, in comparison to stimulation with
TGF-β2 and without inhibitors
Fig. 5 Effects of wortmannin on TGF-β2-induced Smad-mut/Luc
promoter activity in ARPE-19 cells. Transfected cells were pretreated
with or without wortmannin and incubated in the presence or absence
of TGF-β2 (10 ng/ml) for 24 hours. Results are expressed relative to
untreated control cells. Values represent the means ± SD of three
independent experiments. *P<0.01, in comparison to stimulation with
TGF-β2 and without inhibitors
Fig. 7 Effects of wortmannin on TGF-β2-induced Smad7 mRNA
expression. Quiescent cell were pretreated with or without wortman-
nin and incubated in the presence or absence of TGF-β2 (10 ng/ml)
for 24 hours. The relative levels of mRNA were normalized against
GAPDH from the same cDNA preparation. Values represent the means ±
SD of three independent experiments. *P<0.05, in comparison to
stimulation with TGF-β2 and without inhibitors
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with ECM production through different pathways, such as
Smads [28–30], p38MAPK [11, 22, 31], and RhoA/Rho-
kinase [23, 24] in some cell types.
A few studies have suggested that TGF-β stimulates the
PI3K/Akt signaling pathway, which regulates type I
collagen expression in some cell types [18–20]. TGF-β1
activates Akt, a downstream target of PI3K, in human
mesangial cells and dermal fibroblasts. Inhibition of the
PI3K abrogates TGF-β1-stimulated COL1A2 gene transcrip-
tion. These results are consistent with the present results with
COL1A2 in human retinal pigment epithelial cells.
Smads, the downstream target of TGF-β,a r et h em a j o r
transduction pathways between cell surface TGF-β receptors
and gene promoters [32, 33].
Receptor-regulated Smad2 and Smad3 are activated and
phosphorylated by the activated receptor complex com-
posed of type I and type II serine/threonine kinase
receptors. Smad2 and Smad3 then form a heterodimer
complex with a common mediator, Smad4. The hetero
oligomeric Smad2/3/4 complex translocates into the nucleus,
where it binds promoters, and mediates transcription of target
genes [32, 33]. Smads are influenced by multiple signaling
pathways including p38MAPK [11, 22]a n dR h o[ 23]i n
ARPE-19. The PI3K/Akt pathway mediates Smad3 activity
in some cell types [18, 20]. The activation of PI3K pathway
by TGF-β1 enhances Smad3 transcriptional activity in
human mesangial cells, leading to increased collagen I
expression. However, activation of the PI3K pathway alone
is not sufficient to increase COL1A2 gene expression. This
report suggests that PI3K can modulate type I collagen
expression only when the Smad proteins also are activated
[18]. The current study evaluated the effects of wortmannin
on the transcriptional activity of Smad3 using CAGA12-Luc.
Wortmannin significantly reduced the TGF-β2-induced
activity of CAGA12-Luc. This finding indicated that the
PI3K/Akt pathway mediates the induction of COL1A2
gene expression by TGF-β2 in ARPE-19 cells via
Smad3 transcriptional activity. However, treatment with
wortmannin also significantly reduced TGF-β2i n d u c -
tion of the Smad-mut/Luc promoter activity. This
indicated that the PI3K/Akt pathway mediates the
COL1A2 gene expression by TGF-β2i nA R P E - 1 9c e l l s
without Smad3 activity as well. So the PI3K/Akt
pathway probably mediates type I collagen expression
by TGF-β2 in ARPE-19 cells through Smad-dependent
and Smad-independent pathways.
Smad7 is the inhibitory Smad, which inhibits phosphory-
lation of Smad2/3 and thus attenuates nuclear translocation of
the Smad complex [34]. Several studies demonstrate that
overexpressing Smad7 attenuates collagen synthesis induced
by TGF-β1[ 35]. Therefore, introducing Smad7 is of
therapeutic value in pathological tissue fibrosis. With respect
to the role of Smad7 in PVR, Smad7 gene transfer
suppresses fibrogenic responses to TGF-β2 by RPE in vitro
and in vivo [36]. The current study showed that inhibition of
the PI3K/Akt pathway with wortmannin increases Smad7
mRNA expression in ARPE-19 cells. Negative modulation
of Smad3 phosphorylation by Smad7 may contribute to
the downregulation of collagen production in ARPE-19
cells and inhibition of the PI3K/Akt pathway may
induce Smad7 upregulation.
Several reports have indicated the importance of the
PI3K/Akt pathway in pathogenesis of PVR. Inhibition of
the PI3K/Akt pathway regulates monocyte chemotactic
protein (MCP)-1 in human RPE cells, which is detected in
the vitreous in PVR [37]. Moreover, blocking PI3K inhibits
the collagen gel contraction induced by PDGF [38]. The
current study showed that inhibition of the PI3K/Akt
pathway suppressed the TGF-β2-induced type I collagen
expression in human retinal pigment epithelial cells. The
PI3K/Akt pathway may therefore be a new therapeutic
target for treating PVR.
The limitations of our studies are as follows. First, our
studies were performed in RPE culture on plastic plates;
this condition does not duplicate the microenvironment that
is present in vivo. Therefore, the role of the PI3K/Akt
pathway should be further investigated in PVR animal
models. Next, we used wortmannin as an inhibitor of
the PI3K/Akt pathway. Although many published
articles consider it a specific inhibitor of PI3K,
wortmannin also inhibits the MAPK pathway independent
of its effects on PI3K [39–41]. This is of special concern, as
all experiments were built on the use of this chemical.
Further experiments should thus be done to determine
whether wortmannin inhibits another TGF-β2-induced signal
pathway in RPE.
We previously showed that the inhibition of the TGF-
β2/non-Smad signaling pathway, including p38MAPK
[22] and RhoA/Rho-kinase [23], suppresses the expression
of type I collagen induced by TGF-β2i nR P E .W eh a v e
herein shown that the PI3K/Akt pathway is also involved
in TGF-β2-induced type I collagen synthesis in RPE. It is
therefore necessary to further analyze the cross-talk
between p38MAPK and RhoA/Rho-kinase and PI3K/Akt
in relaying the TGF-β2 signal to type I collagen
production in RPE.
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